The content on this site is intended for healthcare professionals only
Dr Stahler speaks with ecancer at ESMO 2016 about his research targeting FGF2 expression against chemoresistance in colorectal cancer (CRC) 3 cell lines, with expression levels have a potentially predictive value for patient response.
He summarises the results in cell lines and how this has translated to predicted and actual patient response.
Dr Stahler notes that this was an exploratory trial, and considers avenues of further upcoming validation trials.
Addressing the rise of multiple myeloma in Rwanda
Best practice in HRRm testing in patients with metastatic prostate cancer
Colorectal cancer risk factors in Nigeria
The genomics of cancer in Africa
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert Round Up for August 4th - 10th, 2023
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Choosing Wisely in pathology
CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC
